LLY

1,046.81

+0.65%↑

JNJ

242.17

-0.46%↓

ABBV

232.01

+0.26%↑

NVS

165.93

+1.92%↑

MRK

121.59

+0.21%↑

LLY

1,046.81

+0.65%↑

JNJ

242.17

-0.46%↓

ABBV

232.01

+0.26%↑

NVS

165.93

+1.92%↑

MRK

121.59

+0.21%↑

LLY

1,046.81

+0.65%↑

JNJ

242.17

-0.46%↓

ABBV

232.01

+0.26%↑

NVS

165.93

+1.92%↑

MRK

121.59

+0.21%↑

LLY

1,046.81

+0.65%↑

JNJ

242.17

-0.46%↓

ABBV

232.01

+0.26%↑

NVS

165.93

+1.92%↑

MRK

121.59

+0.21%↑

LLY

1,046.81

+0.65%↑

JNJ

242.17

-0.46%↓

ABBV

232.01

+0.26%↑

NVS

165.93

+1.92%↑

MRK

121.59

+0.21%↑

Search

Twist Bioscience Corp

Открыт

СекторЗдравоохранение

51.23 4.3

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

48.61

Макс.

51.32

Ключевые показатели

By Trading Economics

Доход

-3.4M

-31M

Продажи

4.7M

104M

Рентабельность продаж

-29.419

Сотрудники

979

EBITDA

-3.2M

-24M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+5.88% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

4 мая 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

309M

2.9B

Предыдущая цена открытия

46.93

Предыдущая цена закрытия

51.23

Новостные настроения

By Acuity

50%

50%

148 / 351 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

16 февр. 2026 г., 22:17 UTC

Отчет
Приобретения, слияния, поглощения

BHP 1st Half Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16 февр. 2026 г., 23:48 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

16 февр. 2026 г., 23:48 UTC

Обсуждения рынка

Nikkei May Decline; Prime Minister Takaichi's Policy Steps in Focus -- Market Talk

16 февр. 2026 г., 23:23 UTC

Приобретения, слияния, поглощения

BHP Shares Up 7.0% After Silver Streaming Deal, Profit Beat

16 февр. 2026 г., 23:20 UTC

Приобретения, слияния, поглощения

BHP Exploring Other Infrastructure Deals as It Chases $10 Billion Target - Interview

16 февр. 2026 г., 22:48 UTC

Приобретения, слияния, поглощения

BHP CFO: Brokers Value BHP's Total Stake in Antamina Around $4.5 Billion

16 февр. 2026 г., 22:48 UTC

Приобретения, слияния, поглощения

BHP CFO: Has Desalination, Other Power Assets on Which Deals Could Be Considered

16 февр. 2026 г., 22:48 UTC

Приобретения, слияния, поглощения

BHP CFO: Wants to Make Sure It Does Not Give Up Any Strategic, Operational Control of Assets

16 февр. 2026 г., 22:48 UTC

Приобретения, слияния, поглощения

BHP CFO: Will Allocate Cash From Asset Deals to Growth, Shareholder Returns

16 февр. 2026 г., 22:47 UTC

Приобретения, слияния, поглощения

BHP CFO: Won't Put Deadline on $10 Billion Cash Unlock Target

16 февр. 2026 г., 22:47 UTC

Приобретения, слияния, поглощения

BHP CFO: Bar Very High For Asset Deals

16 февр. 2026 г., 22:47 UTC

Приобретения, слияния, поглощения

BHP CFO: Sees 'Quite a Lot of Opportunities' in Potential Infrastructure Deals

16 февр. 2026 г., 22:35 UTC

Обсуждения рынка

Australian Jobs Data Could Confirm Market Too Tight -- Market Talk

16 февр. 2026 г., 22:02 UTC

Отчет
Приобретения, слияния, поглощения

BHP 1H Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16 февр. 2026 г., 21:48 UTC

Отчет
Приобретения, слияния, поглощения

BHP: Optimistic That Economic Backdrop Supportive For Key Commodities

16 февр. 2026 г., 21:48 UTC

Приобретения, слияния, поглощения

Wheaton Precious Metals: Acquisition Immediately Increases Production and Cash Flow Profile

16 февр. 2026 г., 21:48 UTC

Отчет
Приобретения, слияния, поглощения

BHP: China's Economy Resilient; India Continues to Outperform

16 февр. 2026 г., 21:47 UTC

Отчет
Приобретения, слияния, поглощения

BHP: Streaming, WAIO Power Deals Unlock Over $6 Billion of Cash Combined

16 февр. 2026 г., 21:47 UTC

Отчет
Приобретения, слияния, поглощения

BHP: Sees Potential to Unlock Up to $10 Billion From Portfolio, Asset Management

16 февр. 2026 г., 21:47 UTC

Приобретения, слияния, поглощения

Wheaton Precious Metals to Have Combined 67.5% of All the Silver Produced From Antamina, Up From 33.75% Currently

16 февр. 2026 г., 21:46 UTC

Приобретения, слияния, поглощения

Wheaton Precious Metals: Upfront Payment to Be Funded Through Combination of Existing Liquidity and New Financing

16 февр. 2026 г., 21:46 UTC

Приобретения, слияния, поглощения

Wheaton Precious Metals Will Pay BHP Total Upfront Cash Consideration of $4.3B on Closing

16 февр. 2026 г., 21:46 UTC

Отчет
Приобретения, слияния, поглощения

BHP Interim Dividend Represents 60% Payout Ratio

16 февр. 2026 г., 21:46 UTC

Приобретения, слияния, поглощения

Wheaton Precious Metals in Definitive Precious Metals Purchase Agreement BHP Subsidiary for Its 33.75% Portion of Silver Produced at Antamina Mine in Peru

16 февр. 2026 г., 21:45 UTC

Отчет
Приобретения, слияния, поглощения

BHP: Copper Contributed 51% of 1H Underlying Ebitda

16 февр. 2026 г., 21:43 UTC

Отчет
Приобретения, слияния, поглощения

BHP Net Debt $14.69 Billion at Dec. 31, Up 25% On-Year

16 февр. 2026 г., 21:43 UTC

Отчет
Приобретения, слияния, поглощения

BHP 1H Net Operating Cash Flow $9.37 Billion, Up 13% On-Year

16 февр. 2026 г., 21:42 UTC

Отчет
Приобретения, слияния, поглощения

BHP 1H Underlying Ebitda $15.46 Billion, Up 25% On-Year

16 февр. 2026 г., 21:42 UTC

Отчет
Приобретения, слияния, поглощения

BHP Was Expected to Record Underlying Profit of $6.03 Billion According to Visible Alpha

16 февр. 2026 г., 21:41 UTC

Отчет
Приобретения, слияния, поглощения

BHP 1H Underlying Profit $6.20 Billion, Up 22% On-Year

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

5.88% рост

Прогноз на 12 месяцев

Средняя 52 USD  5.88%

Максимум 58 USD

Минимум 50 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

6 ratings

6

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

148 / 351Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat